Clinical Trial Update: Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating hyperpolarized carbon metabolic imaging as a biomarker in multiple sclerosis, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Snippet

Sponsor: Ari Green | Conditions: Multiple Sclerosis, RRMS | Phase 2 | Status: NOT_YET_RECRUITING